Answers are grounded in this paper and cite their sources.
Evaluates bioequivalence and effectiveness of self-administered zilucoplan in gMG patients, indicating potential for improved delivery methods.
DV0012 study (NCT06511076): establish bioequivalence of zilucoplan pharmacokinetics (PK) after a single subcutaneous injection with zilucoplan pre-filled auto-injector pen (ZLP-AI) and pre-filled syringe (ZLP-PFS) in healthy volunteers. DV0013 study (NCT06471361): evaluate effectiveness and safety of ZLP-AI self-administration in patients with generalized myasthenia gravis (gMG).
No takes yet. Share an insight, caveat, or question.
Petrulis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: